Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to evaluate the effect of Enoxaparin (LMWH) on the incidence of AV graft thromboses in patients on chronic hemodialysis.

Primary efficacy end point of the study: to compare the time of onset of a new thrombotic event after successful angiography of the AV graft.

Pprimary safety outcome of the study: frequency of hemorrhage. Design and methods: Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg of body weight per day or control group (not on Clexane). Patients will be followed for a year or till next AV graft thrombotic occlusion, if it occurs before. In both groups we will compare time periods in months between first and recurrent thrombotic events of AVG by evaluation the difference between two sample means. Also interim analysis of AV grafts patency between the two groups will be evaluated at different time points: three, six and twelve months after randomization. Patients in both groups will receive unfractionated heparin during dialysis session to prevent thrombosis of extracorporeal circulation. Patients from Enoxaparin group will receive a half dose (500 units/hour) to prevent possible risk of bleeding during the session. Before randomization all patients will be evaluated for hypercoagulability state which will include: Factor V Laden deficiency, Anti phospholipid antibodies (APLA), Antithrombin III deficiency and Protein C/S deficiency.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT01970280
Study type Interventional
Source Meir Hospital, Kfar Saba, Israel
Contact Ilan Rozenberg, MD
Phone +97297471734
Email ilan.rozenberg@clalit.org.il
Status Recruiting
Phase Phase 4
Start date September 2013
Completion date January 2015

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06382701 - Effect of Aromatherapy on Pain, Anxiety and Satisfaction in Cannulation N/A
Completed NCT04674930 - Effects of Exercise Program on Physical Functioning of Hemodialysis Patients. N/A
Recruiting NCT02245633 - Correlation Between Vitamin D Levels to ADAMTS13 , VWF and Micro RNA Expression in Diabetic Hemodialysis Patients N/A
Completed NCT06165211 - Nature-Based Sound Application For Hemodialysis Patients N/A
Completed NCT05693584 - The Effect of Using Virtual Reality Glasses on Pain During Fistula Cannulation in Hemodialysis Patients N/A
Completed NCT06106763 - Mandala Colouring On Anxiety, Depression, Pain And Quality of Life N/A
Completed NCT01932853 - Association Between Dose Dialysis by Kt and Mortality N/A
Completed NCT01273974 - The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients Phase 2/Phase 3
Completed NCT04139759 - THE EFFECT OF HAND AND FOOT MASSAGE ON FATIGUE IN HEMODIALYSIS PATIENTS N/A
Not yet recruiting NCT05574595 - Effect on Pain and Comfort Associated With Fistula Puncture N/A
Completed NCT04175652 - Effects of Laughter Yoga on Hemodialysis Patients' Plasma-Beta Endorphin Levels, Pain Levels and Sleep Quality N/A
Not yet recruiting NCT06314243 - The Impact of Pumpkin Seed Oil Supplementation on Hemodialysis Patients Phase 3
Completed NCT01596842 - Effect of Omega-3 Fatty Acid on Vitamin D Activation Phase 4
Enrolling by invitation NCT01896882 - Dietary Sodium Restriction in Hemodialysis Patients N/A
Completed NCT00638300 - Removal of Ligand-bound Iron During Intravenous (IV) Iron Administration in Hemodialysis (HD) N/A
Terminated NCT00259714 - Dialysate Sodium Individualization in Hemodialysis Phase 1
Completed NCT01846754 - Prevalence of Fatigue in Hemodialysis Patients N/A
Completed NCT00491868 - Clinical Study of R744 to Hemodialysis Patients Phase 3
Not yet recruiting NCT06449105 - The Effect of Mindfulness Compassionate Living Practice on Hemodialysis Patients N/A
Completed NCT04195919 - The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients Phase 1